Pulmonary large cell neuroendocrine carcinoma

Summary

Pulmonary large cell neuroendocrine carcinoma (MONDO:0003960) is a cancer and 15 clinical trials. Top therapeutic interventions include pembrolizumab, tarlatamab, and benmelstobart. A subtype of lung large cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 15

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pulmonary large cell neuroendocrine carcinoma
Mondo ID	MONDO:0003960
DOID	DOID:6658
NCIT	C5672
UMLS	C1334363
MedGen	233608
GARD	0023754
Anatomy (UBERON)	UBERON:0002048
Is cancer (heuristic)	yes

Also known as: large cell lung carcinoma with neuroendocrine differentiation · large cell lung neuroendocrine carcinoma · large cell neuroendocrine carcinoma of lung · large cell neuroendocrine carcinoma of the lung · LCNEC of the lung · lung large cell neuroendocrine carcinoma · pulmonary large cell neuroendocrine carcinoma

Data availability: 6 cell lines.

Disease family

This is a subtype of lung large cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › large cell carcinoma › lung large cell carcinoma › pulmonary large cell neuroendocrine carcinoma

Related subtypes (6): basaloid large cell lung carcinoma, lung occult large cell carcinoma, large cell carcinoma with rhabdoid phenotype, lung sarcomatoid carcinoma, lymphoepithelioma-like lung carcinoma, large cell lung carcinoma, clear cell variant

Subtypes (1): lung combined large cell neuroendocrine carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	9
PHASE1	5
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05470595	PHASE2	ACTIVE_NOT_RECRUITING	A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
NCT06393816	PHASE2	RECRUITING	FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
NCT06418087	PHASE2	RECRUITING	Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)
NCT06814496	PHASE1/PHASE2	RECRUITING	Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
NCT07510594	PHASE2	NOT_YET_RECRUITING	A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC
NCT07561645	PHASE2	NOT_YET_RECRUITING	A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung
NCT02755675	PHASE2	UNKNOWN	uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
NCT02943798	PHASE2	UNKNOWN	Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma
NCT03901378	PHASE2	WITHDRAWN	Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
NCT04010357	PHASE2	COMPLETED	Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
NCT05680922	PHASE1	ACTIVE_NOT_RECRUITING	DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
NCT06736418	PHASE1	ACTIVE_NOT_RECRUITING	Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
NCT07006727	PHASE1	RECRUITING	Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
NCT07080242	PHASE1	RECRUITING	Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT06049966	PHASE1	COMPLETED	Atezolizumab in Large Cell Neuroendocrine Carcinoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PEMBROLIZUMAB	4	1
TARLATAMAB	4	1
BENMELSTOBART	3	1
PLATINUM	3	1
OBRIXTAMIG	2	1